Marc R. Birtwistle

Marc R. Birtwistle

Auto-generated profile, based on publicly available information

Marc R. Birtwistle

Affiliations Department of Chemical and Biomolecular Engineering, Clemson University, Clemson, South Carolina, United States of America, Department of Bioengineering, Clemson University, Clemson, South Carolina, United States of America

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Genes & Cancer
Verified
Journal Article
Closed access
David MatallanasDavid Matallanas
David Matallanas
MBM. Birtwistle
M. Birtwistle
DRD. Romano
D. Romano
Armin ZebischArmin Zebisch
Armin Zebisch
JRJens Rauch
Jens Rauch
Walter KolchWalter Kolch
Walter Kolch
First identified in the early 1980s as retroviral oncogenes, the Raf proteins have been the objects of intense research. The discoveries 10 years later that the Raf family members (Raf-1, B-Raf, and A-Raf) are bona fide Ras effectors and upstream activators of the ubiquitous ERK pathway increased the interest in these proteins primarily because of the central role that this cascade plays in cancer development. The important role of Raf in cancer was corroborated in 2002 with the discovery of B-Raf genetic mutations in a large number of tumors. This led to intensified drug development efforts to target Raf signaling in cancer. This work yielded not only recent clinical successes but also surprising insights into the regulation of Raf proteins by homodimerization and heterodimerization. Surprising insights also came from the hunt for new Raf targets. Although MEK remains the only widely accepted Raf substrate, new kinase-independent roles for Raf proteins have emerged. These include the regulation of apoptosis by suppressing the activity of the proapoptotic kinases, ASK1 and MST2, and the regulation of cell motility and differentiation by controlling the activity of Rok-α. In this review, we discuss the regulation of Raf proteins and their role in cancer, with special focus on the interacting proteins that modulate Raf signaling. We also describe the new pathways controlled by Raf proteins and summarize the successes and failures in the development of efficient anticancer therapies targeting Raf. Finally, we also argue for the necessity of more systemic approaches to obtain a better understanding of how the Ras-Raf signaling network generates biological specificity.

1 July 2015 in Neuron
Verified
Journal Article
Closed access
IMIan Maze
Ian Maze
WWWendy Wenderski
Wendy Wenderski
KNKyung-Min Noh
Kyung-Min Noh
RBRosemary C. Bagot
Rosemary C. Bagot
NTNikos Tzavaras
Nikos Tzavaras
CAC. David Allis
C. David Allis

1 May 2010 in Cell
Verified
Journal Article
Closed access
TNTakashi Nakakuki
Takashi Nakakuki
MBMarc R. Birtwistle
Marc R. Birtwistle
YSYuko Saeki
Yuko Saeki
NYNoriko Yumoto
Noriko Yumoto
KIKaori Ide
Kaori Ide
BKBoris N. Kholodenko
Boris N. Kholodenko

22 November 2009 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
AKAlex Von Kriegsheim
Alex Von Kriegsheim
DBDaniela Baiocchi
Daniela Baiocchi
MBMarc Birtwistle
Marc Birtwistle
DSDavid Sumpton
David Sumpton
Willy V. BienvenutWilly V. Bienvenut
Willy V. Bienvenut
Walter KolchWalter Kolch
Walter Kolch

27 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAndrea Degasperi
Andrea Degasperi
MBMarc R. Birtwistle
Marc R. Birtwistle
NVNatalia Volinsky
Natalia Volinsky
JRJens Rauch
Jens Rauch
Walter KolchWalter Kolch
Walter Kolch
BKBoris N. Kholodenko
Boris N. Kholodenko
Western blot data are widely used in quantitative applications such as statistical testing and mathematical modelling. To ensure accurate quantitation and comparability between experiments, Western blot replicates must be normalised, but it is unclear how the available methods affect statistical properties of the data. Here we evaluate three commonly used normalisation strategies: (i) by fixed normalisation point or control; (ii) by sum of all data points in a replicate; and (iii) by optimal alignment of the replicates. We consider how these different strategies affect the coefficient of variation (CV) and the results of hypothesis testing with the normalised data. Normalisation by fixed point tends to increase the mean CV of normalised data in a manner that naturally depends on the choice of the normalisation point. Thus, in the context of hypothesis testing, normalisation by fixed point reduces false positives and increases false negatives. Analysis of published experimental data shows that choosing normalisation points with low quantified intensities results in a high normalised data CV and should thus be avoided. Normalisation by sum or by optimal alignment redistributes the raw data uncertainty in a mean-dependent manner, reducing the CV of high intensity points and increasing the CV of low intensity points. This causes the effect of normalisations by sum or optimal alignment on hypothesis testing to depend on the mean of the data tested; for high intensity points, false positives are increased and false negatives are decreased, while for low intensity points, false positives are decreased and false negatives are increased. These results will aid users of Western blotting to choose a suitable normalisation strategy and also understand the implications of this normalisation for subsequent hypothesis testing.

21 December 2010 in Science Signaling
Verified
Journal Article
Closed access
PDF file
OSOliver E. Sturm
Oliver E. Sturm
RORichard Orton
Richard Orton
JGJoan Grindlay
Joan Grindlay
MBMarc Birtwistle
Marc Birtwistle
VVVladislav Vyshemirsky
Vladislav Vyshemirsky
Walter KolchWalter Kolch
Walter Kolch
Analysis of ERK pathway circuitry suggests appropriate targets for inhibition, providing a guide for drug development.